BELITE BIO, INC

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases, specifically Geographic Atrophy (GA) and Stargardt disease type 1 (STGD1), and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout ⁷⁶. The company's core business model revolves around the research and development of small molecule, orally administered compounds to address significant unmet medical needs in these therapeutic areas ⁷⁶. Revenue generation is currently not from product sales, as all product candidates are in clinical or preclinical development ²³. The primary customer segments, if products are approved, would be patients suffering from STGD1, GA, NAFLD, NASH, T2D, and gout ⁷⁶.

The company's lead product candidate, tinlarebant (a/k/a LBS-008), is an orally administered, once-a-day tablet designed as an early intervention for maintaining retinal health in STGD1 and GA patients ⁷⁷. Tinlarebant functions as a potent and reversible RBP4 antagonist, reducing retinol delivery to the eye to decrease bisretinoid accumulation, which is implicated in the progression of STGD1 and GA ⁷⁷. The company holds a worldwide exclusive license for the RBP4 intellectual property portfolio from Columbia University, covering over 400 structurally distinct RBP4 antagonists under patent protection in major pharmaceutical markets globally ⁷⁷.

For STGD1, tinlarebant has completed Phase 1 SAD studies in 40 healthy adult subjects in the U.S. and 39 healthy adult subjects in Australia, and a Phase 1 MAD study in 32 healthy adult subjects in Australia ⁷⁷. An open-label, dose-finding Phase 1b/2 clinical trial in adolescent STGD1 subjects in Australia and Taiwan involved 11 subjects in Phase 1b and 13 subjects in Phase 2, with 12 subjects completing the 24-month Phase 2 portion ⁷⁷. The Phase 3 DRAGON trial in adolescent STGD1 patients (aged 12 to 20 years) enrolled 104 subjects and announced top-line results in December 2025 ⁷⁸. An additional Phase 2/3 clinical trial, DRAGON II, is ongoing in Japan, the United States, and the United Kingdom, with 73 subjects enrolled, including 15 Japanese subjects, to facilitate future NDA applications in Japan ⁷⁹.

In the Phase 3 DRAGON trial for STGD1, tinlarebant demonstrated a 35.7% reduction in the annualized macular lesion growth rate compared to placebo, which was highly statistically significant (p=0.0033) ⁷⁸. A post-hoc analysis using an autoregressive covariance matrix yielded a p-value of <0.0001 ⁷⁸. Tinlarebant (5 mg orally, daily) was well tolerated, with no study drug discontinuations due to non-ocular adverse events and four related to ocular adverse events ⁷⁸. The most common drug-related ocular adverse events were xanthopsia and delayed dark adaptation, mostly mild and resolved during the trial ⁷⁸. Headaches were the most commonly reported treatment-related non-ocular adverse events ⁷⁸.

For GA, tinlarebant has completed Phase 1 trials in healthy adult subjects and a Phase 1b dose-finding trial in aged healthy adults in Australia to determine an optimal dose [79, 84]. A global, multicenter, randomized, double-masked, placebo-controlled Phase 3 trial named "PHOENIX" has commenced in the U.S., the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia, with patient enrollment completed for a total of 530 subjects [79, 84].

The company's other drug development pipeline candidate, LBS-009, is an anti-RBP4 oral therapy targeting liver diseases such as NAFLD, NASH, and T2D ⁸⁴. LBS-009 is currently in preclinical development ⁸⁵.

For the year ended December 31, 2025, the company reported a net loss of approximately US$77.6 million ²³. The accumulated deficit as of December 31, 2025, was approximately US$185.3 million ²³. Net cash used in operating activities for the year ended December 31, 2025, was approximately US$40.7 million ²². The company's financial position is characterized by significant cash consumption due to ongoing research and development activities ²².

Comparing year-over-year, net cash used in operating activities increased from approximately US$29.8 million in 2023 and US$29.2 million in 2024 to US$40.7 million in 2025 ²². Net losses also increased from approximately US$31.6 million in 2023 and US$36.1 million in 2024 to US$77.6 million in 2025 ²³. These figures reflect increased expenses associated with advancing product candidates through clinical trials and operating as a public company ²³.

Significant operational developments during the period include the announcement of top-line results for the Phase 3 DRAGON trial in December 2025, with an expected NDA submission to the FDA in the second quarter of 2026 [78, 92]. The company also completed patient enrollment for the Phase 3 PHOENIX trial for GA with 530 subjects [79, 84]. In May 2025, the FDA granted Breakthrough Therapy Designation for tinlarebant for STGD1 ⁷⁹. Tinlarebant also received Orphan Drug Designation in Japan in February 2024 and Sakigake (Pioneer Drug) Designation by the MHLW in Japan in June 2024 for STGD1 ⁷⁹. The company completed an underwritten follow-on offering in December 2025, raising approximately US$350.0 million ⁷⁶.

Management expects to submit a New Drug Application (NDA) to the FDA for tinlarebant for the treatment of STGD1 in the second quarter of 2026 [78, 92]. No specific revenue, margin, or EPS guidance for the upcoming period is provided in the filing.

A major growth vector for the company is the continued development and potential commercialization of tinlarebant for STGD1. The successful achievement of the primary endpoint in the Phase 3 DRAGON trial, demonstrating a 35.7% reduction in annualized macular lesion growth rate (p=0.0033), supports this growth [78, 92]. The Breakthrough Therapy Designation from the FDA, Orphan Drug Designation in the United States, Europe, and Japan, and Sakigake (Pioneer Drug) Designation in Japan for STGD1 are expected to accelerate the regulatory review and approval process, potentially leading to earlier market entry ⁷⁹. The company also intends to use data from the DRAGON II trial, which includes 15 Japanese subjects, to facilitate future NDA applications in Japan [79, 93].

Another significant growth area is the development of tinlarebant for Geographic Atrophy (GA) associated with dry AMD. The company has completed patient enrollment for the global, multicenter, randomized, double-masked, placebo-controlled Phase 3 PHOENIX trial, with a total of 530 subjects [79, 84]. An interim analysis is expected for the PHOENIX trial ⁹⁷. The rationale for tinlarebant in GA is based on the strong pathophysiologic similarities between STGD1 and GA, both characterized by the accumulation of toxic vitamin A by-products ⁸³.

The company is also advancing LBS-009, an anti-RBP4 oral therapy, which is currently in preclinical development, targeting metabolic diseases such as NAFLD, NASH, and T2D [84, 85]. Preclinical studies with LBS-009 have shown the ability to reduce RBP4 levels in healthy rats by 85% following a single dose and ameliorate steatosis in transgenic mice, suggesting potential as a pharmacotherapy for NASH ⁹⁹.

Operationally, the company anticipates increased expenses as it continues to develop and conduct clinical trials for tinlarebant, initiates new research and preclinical development for future product candidates, and seeks regulatory approvals ²³. Significant commercialization expenses related to product sales, marketing, manufacturing, and distribution are also expected if any product candidates obtain marketing approval ²³. The company is in the process of building an in-house commercialization team and sales force, which will require significant capital expenditures, management resources, and time ¹⁸.

The company's capital allocation plans include continued substantial investment in research and development, as evidenced by the ongoing clinical trials for tinlarebant in STGD1 and GA [23, 78, 79]. The company has financed its operations primarily through equity offerings, including an underwritten follow-on offering in December 2025 that raised approximately US$350.0 million [22, 76]. The company will require further funding through public or private equity offerings, debt financings, collaborations, and licensing arrangements ²². The company has made payments to Columbia University totaling US$4 million upon completion of certain clinical trial related milestones and expects to make additional payments of US$6 million in the near term when relevant development milestones are achieved ¹⁰⁴.

Management has explicitly flagged several structural headwinds and execution risks. The company's business is highly dependent on the success of tinlarebant, and failure to obtain marketing approval or successfully commercialize it would be detrimental ⁷. All product candidates are in clinical or preclinical development, and delays or failures in completing clinical development and obtaining regulatory approval could materially harm the business ¹⁰. Difficulties in enrolling and retaining patients in clinical trials could delay development and regulatory approvals ¹¹. The manufacture of biopharmaceutical products is complex, and reliance on third-party CMOs for clinical and commercial supplies poses risks of delays, inability to meet specifications, or non-compliance with cGMP regulations [15, 60].

Geographic, regulatory, and macro factors identified as constraints include the time-consuming and evolving regulatory approval processes of the FDA, TGA, NMPA, EMA, and PMDA ¹⁵. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, limiting global commercialization ²⁸. Inadequate funding or disruptions at government agencies like the FDA could hinder regulatory review ³⁰. Changes in U.S. and Chinese regulations, including those related to cross-border data transfer and cybersecurity, may adversely impact business operations, ability to raise capital, and the market price of ADSs [54, 56]. The uncertainty of patent linkage, patent term extension, and data and market exclusivity for NMPA-approved pharmaceutical products in China could increase the risk of early generic competition ³⁷.

The company faces material risks including its high dependence on the success of tinlarebant, with all product candidates currently in preclinical or clinical development, and no history of commercializing pharmaceutical products, leading to a need for substantial additional financing to fund operations [7, 10, 22, 23]. Clinical development is a lengthy, expensive process with uncertain outcomes, and results from earlier studies may not predict future success, potentially leading to delays, increased costs, or termination of trials [9, 12, 14]. Product candidates may cause serious adverse side effects, delaying or preventing regulatory approval or limiting commercialization ¹³. The biopharmaceutical industry is highly competitive, with rapid technological change, and competitors may develop more effective or less costly drugs or achieve earlier regulatory approval ¹⁷. The company has limited experience in launching and marketing products and is building an in-house commercialization team, which requires significant capital and time ¹⁸. Reimbursement for approved products may be limited or unavailable, and unfavorable pricing regulations could harm the business ¹⁹. Intellectual property protection is critical, but obtaining and maintaining patents is expensive, time-consuming, and uncertain, with risks of challenges to validity or enforceability, and potential for third-party infringement [32, 33, 36, 41]. Reliance on third-party CROs and CMOs for preclinical studies, clinical trials, and manufacturing introduces risks of non-compliance, delays, or supply disruptions [59, 60]. The company is subject to changing U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws, with potential for severe penalties for non-compliance ⁵³. Foreign exchange risks exist due to international operations and expenses in local currencies ⁵⁴. Changes in Chinese government policies or U.S.-China relations, including increased scrutiny on China-based operations, could adversely affect business, financial condition, and ADS market price [54, 55]. The company no longer qualifies as an "emerging growth company" and is now a "large accelerated filer," incurring increased compliance costs and disclosure requirements, including auditor attestation for internal control over financial reporting [73, 74]. The company expects to be classified as a passive foreign investment company (PFIC) for the taxable year ended December 31, 2025, and for the current taxable year, which could result in adverse U.S. federal income tax consequences for U.S. investors ⁷³.

Management's message to shareholders emphasizes the company's focus as a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for degenerative retinal diseases and metabolic diseases with significant unmet medical needs ⁷⁶. They highlight the progress of their lead product candidate, tinlarebant, for STGD1 and GA, noting the achievement of the primary endpoint in the Phase 3 DRAGON trial for STGD1 with a 35.7% reduction in annualized macular lesion growth rate (p=0.0033) [78, 92]. Management expects to submit an NDA to the FDA in the second quarter of 2026 for tinlarebant in STGD1 [78, 92]. They also underscore the completion of patient enrollment for the Phase 3 PHOENIX trial for GA, with a total of 530 subjects [79, 84]. Strategic priorities include the continued clinical development and regulatory approval of tinlarebant for STGD1 and GA, expanding the drug pipeline through internal research and potential in-licensing arrangements, and building an in-house commercialization team and sales force [18, 23, 76, 99].